Markets trade on accelerating earnings (which there is none for ACAD), best in class technology, effective management, perception of future earnings. I'd say we have 3 of 4 important elements currently in place. The perception is that earnings will follow, which equals a massive winner. So, in the interim, there's the wild card of buyout offers (any large pharma may make a bid), and it's quite possible a bidding war could develop. Anything can happen in the next 16 months, including positive indications for ADP, and schizophrenia. In the world of biotech, this is as close to a sure thing as you're going to find; a pure play. Fool On!
Well said. Add to that simply the fact that as time goes by and there are no roadblocks, execution risk decreases, discount rate decreases, NPV increases, stock price theoretically increases. This motley fool thinks a company with a blockbuster drug is simply dead money for 16 months? that's not how the market works. PCYC would trade at 0 right now if that was true.